Christopher Liu
Stock Analyst at Leerink Partners
(2.92)
# 1,393
Out of 5,129 analysts
9
Total ratings
83.33%
Success rate
38.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Outperform | $48 | $42.94 | +11.78% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $24.34 | -17.83% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $3.10 | +190.32% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.42 | +313.22% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $9.15 | +96.72% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $31.90 | -15.36% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $103.15 | -59.28% | 1 | Aug 8, 2023 |
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $42.94
Upside: +11.78%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $24.34
Upside: -17.83%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $3.10
Upside: +190.32%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.42
Upside: +313.22%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $9.15
Upside: +96.72%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $31.90
Upside: -15.36%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $103.15
Upside: -59.28%